CORT
Price
$75.75
Change
-$2.64 (-3.37%)
Updated
Nov 13 closing price
Capitalization
7.96B
96 days until earnings call
Intraday BUY SELL Signals
FGEN
Price
$9.07
Change
-$0.06 (-0.66%)
Updated
Nov 13 closing price
Capitalization
36.63M
Intraday BUY SELL Signals
Interact to see
Advertisement

CORT vs FGEN

Header iconCORT vs FGEN Comparison
Open Charts CORT vs FGENBanner chart's image
Corcept Therapeutics
Price$75.75
Change-$2.64 (-3.37%)
Volume$460.71K
Capitalization7.96B
FibroGen
Price$9.07
Change-$0.06 (-0.66%)
Volume$63.26K
Capitalization36.63M
CORT vs FGEN Comparison Chart in %
View a ticker or compare two or three
VS
CORT vs. FGEN commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CORT is a Hold and FGEN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (CORT: $78.39 vs. FGEN: $9.13)
Brand notoriety: CORT and FGEN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CORT: 66% vs. FGEN: 286%
Market capitalization -- CORT: $7.96B vs. FGEN: $36.63M
CORT [@Biotechnology] is valued at $7.96B. FGEN’s [@Biotechnology] market capitalization is $36.63M. The market cap for tickers in the [@Biotechnology] industry ranges from $110.25B to $0. The average market capitalization across the [@Biotechnology] industry is $2.1B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CORT’s FA Score shows that 1 FA rating(s) are green whileFGEN’s FA Score has 0 green FA rating(s).

  • CORT’s FA Score: 1 green, 4 red.
  • FGEN’s FA Score: 0 green, 5 red.
According to our system of comparison, CORT is a better buy in the long-term than FGEN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CORT’s TA Score shows that 5 TA indicator(s) are bullish while FGEN’s TA Score has 4 bullish TA indicator(s).

  • CORT’s TA Score: 5 bullish, 5 bearish.
  • FGEN’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, CORT is a better buy in the short-term than FGEN.

Price Growth

CORT (@Biotechnology) experienced а +2.27% price change this week, while FGEN (@Biotechnology) price change was -17.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.51%. For the same industry, the average monthly price growth was -3.12%, and the average quarterly price growth was +61.90%.

Reported Earning Dates

CORT is expected to report earnings on Feb 18, 2026.

Industries' Descriptions

@Biotechnology (+1.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CORT($7.96B) has a higher market cap than FGEN($36.6M). CORT YTD gains are higher at: 55.567 vs. FGEN (-31.029). CORT has higher annual earnings (EBITDA): 104M vs. FGEN (-77.3M). CORT has more cash in the bank: 342M vs. FGEN (23.4M). CORT has less debt than FGEN: CORT (6.61M) vs FGEN (73.7M). CORT has higher revenues than FGEN: CORT (716M) vs FGEN (7.35M).
CORTFGENCORT / FGEN
Capitalization7.96B36.6M21,760%
EBITDA104M-77.3M-135%
Gain YTD55.567-31.029-179%
P/E Ratio87.02N/A-
Revenue716M7.35M9,747%
Total Cash342M23.4M1,462%
Total Debt6.61M73.7M9%
FUNDAMENTALS RATINGS
CORT vs FGEN: Fundamental Ratings
CORT
FGEN
OUTLOOK RATING
1..100
135
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
93
Overvalued
PROFIT vs RISK RATING
1..100
40100
SMR RATING
1..100
42100
PRICE GROWTH RATING
1..100
4650
P/E GROWTH RATING
1..100
841
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CORT's Valuation (89) in the Pharmaceuticals Other industry is in the same range as FGEN (93) in the Biotechnology industry. This means that CORT’s stock grew similarly to FGEN’s over the last 12 months.

CORT's Profit vs Risk Rating (40) in the Pharmaceuticals Other industry is somewhat better than the same rating for FGEN (100) in the Biotechnology industry. This means that CORT’s stock grew somewhat faster than FGEN’s over the last 12 months.

CORT's SMR Rating (42) in the Pharmaceuticals Other industry is somewhat better than the same rating for FGEN (100) in the Biotechnology industry. This means that CORT’s stock grew somewhat faster than FGEN’s over the last 12 months.

CORT's Price Growth Rating (46) in the Pharmaceuticals Other industry is in the same range as FGEN (50) in the Biotechnology industry. This means that CORT’s stock grew similarly to FGEN’s over the last 12 months.

CORT's P/E Growth Rating (8) in the Pharmaceuticals Other industry is somewhat better than the same rating for FGEN (41) in the Biotechnology industry. This means that CORT’s stock grew somewhat faster than FGEN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CORTFGEN
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
72%
Bullish Trend 2 days ago
85%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
82%
MACD
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
79%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 18 days ago
85%
Declines
ODDS (%)
Bearish Trend 21 days ago
65%
Bearish Trend 2 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
76%
Bullish Trend 2 days ago
81%
Aroon
ODDS (%)
Bearish Trend 2 days ago
42%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
CORT
Daily Signal:
Gain/Loss:
FGEN
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LAMYX26.330.14
+0.53%
Lord Abbett Dividend Growth I
UVALX21.050.08
+0.38%
Victory Value
GMVCX16.300.05
+0.31%
Goldman Sachs Small/Mid Cap Equity C
PRPZX6.320.01
+0.16%
PGIM Jennison Energy Infrastructure Z
VINIX557.510.38
+0.07%
Vanguard Institutional Index I

CORT and

Correlation & Price change

A.I.dvisor indicates that over the last year, CORT has been loosely correlated with VTVT. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if CORT jumps, then VTVT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CORT
1D Price
Change %
CORT100%
-0.78%
VTVT - CORT
49%
Loosely correlated
+6.53%
TENX - CORT
41%
Loosely correlated
-0.71%
AGIO - CORT
41%
Loosely correlated
-0.52%
DNLI - CORT
40%
Loosely correlated
-0.34%
ARCT - CORT
37%
Loosely correlated
-6.23%
More

FGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, FGEN has been loosely correlated with AVTX. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if FGEN jumps, then AVTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FGEN
1D Price
Change %
FGEN100%
-8.15%
AVTX - FGEN
57%
Loosely correlated
-0.45%
AXON - FGEN
43%
Loosely correlated
-0.47%
INSM - FGEN
39%
Loosely correlated
+0.36%
AMRN - FGEN
35%
Loosely correlated
+0.75%
CORT - FGEN
34%
Loosely correlated
-0.78%
More